European HTA harmonisation does not eliminate national evidence needs—strong launch plans must account for both layers. https://www.mattheneus.com/editorial/eu-hta-harmonisation-national-evidence-plans-2026-10-15 #HTA #EvidenceSynthesis #RegulatoryAffairs

Health-data access delays are not just operational friction—they belong in the validity plan. #HTA #EvidenceSynthesis #RegulatoryAffairs https://www.mattheneus.com/editorial/iqwig-gedig-health-data-access-validity-plan-2026-10-13

The UK regulator is strengthening antidepressant warnings on suicide risk and persistent sexual dysfunction, sharpening patient safeguards. https://www.mattheneus.com/editorial/mhra-antidepressant-suicide-pssd-patient-information-safeguards-2026-10-15 #HTA #RegulatoryAffairs #Pharma

Scotland’s deuruxolitinib decision shows how indirect evidence can support class-comparator parity in severe alopecia. https://www.mattheneus.com/editorial/smc-deuruxolitinib-leqselvi-severe-alopecia-itc-comparable-efficacy-2026-10-12 #HTA #MAIC #EvidenceSynthesis

Random walks reveal how uncertainty moves through a network meta-analysis—and where variance diagnostics can expose weak links.
https://www.mattheneus.com/editorial/network-meta-analysis-diffusion-random-walk-variance-diagnostics-2026-10-15
#HTA #NMA #EvidenceSynthesis

When the comparator bridge fails, added benefit can remain unproven—even with active-treatment evidence. https://www.mattheneus.com/editorial/g-ba-iqwig-benralizumab-hes-mepolizumab-indirect-comparison-infeasible-2026-10-15 #HTA #NMA #EvidenceSynthesis #RegulatoryAffairs

A digital diabetes value case can look compelling in year one—but cost-effectiveness depends on what happens when effects wane. https://www.mattheneus.com/editorial/digital-diabetes-matched-cohort-effect-waning-cost-effectiveness-2026-10-14 #HTA #RWE #HealthEconomics

Scotland withheld an acalabrutinib recommendation—not over negative evidence, but because no company submission was made. https://www.mattheneus.com/editorial/smc-acalabrutinib-monotherapy-relapsed-refractory-mcl-non-submission-2026-10-12 #HTA #RegulatoryAffairs #Pharma

Iron deficiency may shift HbA1c enough to distort evidence thresholds. #HTA #EvidenceSynthesis #HealthEconomics https://www.mattheneus.com/editorial/biochemia-medica-iron-deficiency-hba1c-false-elevation-meta-analysis-2026-10-15

Three trials, no head-to-head: a network meta-analysis compares neoadjuvant bladder-cancer strategies. #HTA #NMA #EvidenceSynthesis https://www.mattheneus.com/editorial/pubmed-bladder-cancer-neoadjuvant-ddmvac-durvalumab-network-meta-analysis-2026-10-15

HPV vaccine cost-effectiveness evidence doesn’t travel unchanged.
https://www.mattheneus.com/editorial/hpv-vaccination-economic-evaluation-transferability-price-threshold-screening-context-2026-10-14
#HTA #HealthEconomics #EvidenceSynthesis

Software reversals aren’t always real preference inconsistency. A Nigerian child health valuation study shows why. https://www.mattheneus.com/editorial/nigeria-child-health-state-valuation-software-reversal-preference-inconsistency-2026-10-13 #HTA #HealthEconomics

Scotland’s acoramidis decision shows how a company non-submission can become an access gap for people with ATTR-CM. https://www.mattheneus.com/editorial/smc-acoramidis-beyonttra-attr-cm-non-submission-access-gap-2026-10-12 #HTA #Pharma #RegulatoryAffairs

Highest mean net benefit doesn’t always mean most often optimal. Why the distinction matters in HTA decisions.
https://www.mattheneus.com/editorial/rims1-gastric-surveillance-mean-net-benefit-probability-optimal-2026-10-11
#HTA #HealthEconomics

The MHRA’s 2030 roadmap puts AI-assisted protocol checks and real-world evidence at the centre of regulatory modernization. https://www.mattheneus.com/editorial/mhra-2030-ai-protocol-checker-real-world-evidence-strategy-2026-10-14 #HTA #RWE #RegulatoryAffairs

Dutch payer calls for a 63% zanubrutinib price cut in marginal zone lymphoma—an HTA signal shaped by comparative evidence. https://www.mattheneus.com/editorial/zin-zanubrutinib-brukinsa-marginal-zone-lymphoma-price-cut-maic-2026-09-22 #HTA #MAIC #HealthEconomics #Pharma

Case-only evidence and high cost proved insufficient for targeted import funding in Poland. #HTA #EvidenceSynthesis #RegulatoryAffairs https://www.mattheneus.com/editorial/aotmit-xuriden-dee50-targeted-import-case-series-cost-rejection-2026-09-30

Hospital screening can look cost-saving—until one fragile effectiveness assumption moves. #HTA #HealthEconomics #EvidenceSynthesis https://www.mattheneus.com/editorial/carbapenemase-screening-effectiveness-cost-saving-transferability-2026-10-13

Multinational clinical-trial advice is becoming a permanent part of Europe’s regulatory pathway. #HTA #RegulatoryAffairs #Pharma https://www.mattheneus.com/editorial/ema-act-eu-pre-application-advice-permanent-ctis-2026-10-08